Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction

The clinical value of monitoring of Epstein-Barr virus (EBV) viraemia by quantitative polymerase chain reaction during 1 y was evaluated. 39 recipients of allogeneic hematopoietic stem cell transplantation (SCT) were followed. More than 100 EBV genome equivalents (gEq)/ml in blood or plasma were found in 16/39 patients (41%) at 34 d (range 1–139) post-transplant. Seven of these 16 patients developed EBV disease; 3 post-transplant lymphoproliferative disease (PTLD), 1 myelitis, 1 encephalitis and 2 reactivations with fever. EBV diseases were only found in the high-risk group among recipients of mismatched related or unrelated donor grafts or in patients who underwent reduced-intensity conditioning. In this group, 3/20 (15%) developed PTLD. Conditioning with antithymocyte globulin was significantly associated with EBV disease (p<0.01). EBV load in plasma was more strongly associated with EBV disease than viral load in blood. A cut-off level of 1000 gEq/ml plasma distinguished EBV disease from asymptomatic viraemia, but not PTLD from other EBV diseases. Weekly monitoring of EBV load in plasma in high-risk patients in the first 3 months following SCT seems to be of value for prediction of EBV disease. Therapy for PTLD including rituximab was evaluated during 2 y and showed response in 4/6 cases.

[1]  S. Burrows,et al.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. , 2000, Annual review of microbiology.

[2]  B. Somer,et al.  REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 , 2001, Transplantation.

[3]  J. Niland,et al.  Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. , 1997, The Journal of infectious diseases.

[4]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[5]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[6]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[7]  H. Bobby Gaspar,et al.  Increased incidence of EBV‐related disease following paediatric stem cell transplantation with reduced‐intensity conditioning , 2005, British journal of haematology.

[8]  L. Robison,et al.  Malignant neoplasms following bone marrow transplantation. , 1996, Blood.

[9]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[10]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[11]  D. Porter,et al.  Post-transplant lymphoproliferative disorder: a review , 2003, Bone Marrow Transplantation.

[12]  K. Cornetta,et al.  Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. , 1998, Blood.

[13]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[14]  K. Roemer,et al.  Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease , 2002, Journal of Clinical Microbiology.

[15]  S. Knuutila,et al.  High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment , 2003, Bone Marrow Transplantation.

[16]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Labopin,et al.  Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group , 2005, Bone Marrow Transplantation.

[18]  S. Spijkers,et al.  Active Epstein–Barr virus infection after allogeneic stem cell transplantation: re‐infection or reactivation? , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[19]  A. Toubert,et al.  Epstein-barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy , 2004, Transplantation.

[20]  H. Deeg,et al.  Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. , 1989, The New England journal of medicine.

[21]  B. Burke,et al.  Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. , 1988, Blood.

[22]  A. Bacigalupo.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects , 2005, Bone Marrow Transplantation.

[23]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[24]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[25]  L. Robison,et al.  New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Gross,et al.  Epstein–Barr virus associated disease following blood or marrow transplant , 2003, Pediatric transplantation.

[27]  T. Habermann,et al.  Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era , 2005, Leukemia & lymphoma.

[28]  G. Palù,et al.  The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation , 2005, British journal of haematology.

[29]  K. Falk,et al.  Detection of Epstein-Barr Virus, but not Human Herpesvirus 8, DNA in Cervical Secretions From Swedish Women by Real-Time Polymerase Chain Reaction , 2001, Sexually transmitted diseases.

[30]  J Wagner,et al.  B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome , 1999, Bone Marrow Transplantation.

[31]  A. Fischer,et al.  Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children , 2001, British journal of haematology.

[32]  J. Torre-Cisneros,et al.  Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[33]  E. Kieff,et al.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.

[34]  E. Kieff,et al.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. , 1999, Transplantation.

[35]  A. Klimczak,et al.  B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. , 2003, Transplantation proceedings.

[36]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[37]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.